The initiation of this trial is based on the positive results of P-I/II study evaluating gotistobart alone and in combination with pembrolizumab in patients with advanced solid tumors
The first patient has been treated in P-III trial (PRESERVE-003) evaluating the safety and efficacy of gotistobart as monotx. vs docetaxel in the patient (n= ~600) with NSCLC that progressed under previous PDL1 inhibitors across the US, the EU, and others
The trial is part of BioNTech’s strategy to initiate multiple pivotal trials in 2023 and 2024. The 1EP is OS while 2EPs are ORR, PFS, and AEs. In Mar 2023, both companies collaborated. Earlier it received FTD based on data of P-I/II for the monotx. in metastatic, immunotherapy-resistant NSCLC
Ref: Globenewswire | Image: Biontech
Related News:- Pfizer and BioNTech Receive the US FDA’s EUA for Omicron BA.4/BA.5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
